The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition
Abstract
Natural, extracellular membrane vesicles secreted by Gram-negative bacteria, outer membrane vesicles (OMVs), contain numerous pathogen-associated molecular patterns which can activate systemic immune responses. Previous studies have shown that OMVs induce strong IFN-γ- and T cell-mediated anti-tumor effects in mice. However, IFN-γ is known to upregulate immunosuppressive factors in the tumor microenvironment, especially the immune checkpoint programmed death 1 ligand 1 (PD-L1), which may hamper T cell function and limit immunotherapeutic effectiveness. Here, we report the development of genetically engineered OMVs whose surface has been modified by insertion of the ectodomain of programmed death 1 (PD1). This genetic modification does not affect the ability of OMVs to trigger immune activation. More importantly, the engineered OMV-PD1 can bind to PD-L1 on the tumor cell surface and facilitate its internalization and reduction, thereby protecting T cells from the PD1/PD-L1 immune inhibitory axis. Through the combined effects of immune activation and checkpoint suppression, the engineered OMVs drive the accumulation of effector T cells in the tumor, which, in turn, leads to a greater impairment of tumor growth, compared with not only native OMVs but also the commonly used PD-L1 antibody. In conclusion, this work demonstrates the potential of bioengineered OMVs as effective immunotherapeutic agents that can comprehensively regulate the tumor immune microenvironment to effect markedly increased anti-tumor efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions
Schwechheimer, C., & Kuehn, M. J. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3525 · Cited by 1,922
Immunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140
Immune modulation by bacterial outer membrane vesicles
Kaparakis-Liaskos, M., & Ferrero, R. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3837 · Cited by 1,019
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778
Peripheral T cell expansion predicts tumour infiltration and clinical response
Wu, T. D., Madireddi, S., de Almeida, P. E., Banchereau, R., Chen, Y.-J. J., Chitre, A. S., Chiang, E. Y., Iftikhar, H., O’Gorman, W. E., Au-Yeung, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2056-8 · Cited by 770
Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response
Kim, O. Y., Park, H. T., Dinh, N. T. H., Choi, S. J., Lee, J., Kim, J. H., Lee, S.-W., & Gho, Y. S. (2017) · Nature Communications · doi:10.1038/s41467-017-00729-8 · Cited by 616
Ready, N., Hellmann, M. D., Awad, M. M., Otterson, G. A., Gutierrez, M., Gainor, J. F., Borghaei, H., Jolivet, J., Horn, L., Mates, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01042 · Cited by 581
Gujrati, V., Kim, S., Kim, S.-H., Min, J. J., Choy, H. E., Kim, S. C., & Jon, S. (2014) · ACS Nano · doi:10.1021/nn405724x · Cited by 543
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
Wang, C., Sun, W., Ye, Y., Hu, Q., Bomba, H. N., & Gu, Z. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0011 · Cited by 526
Petousis-Harris, H., Paynter, J., Morgan, J., Saxton, P., McArdle, B., Goodyear-Smith, F., & Black, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31449-6 · Cited by 457
Immuno-Oncology: Emerging Targets and Combination Therapies
Marshall, H. T., & Djamgoz, M. B. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00315 · Cited by 301
PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy
Zhang, X., Wang, C., Wang, J., Hu, Q., Langworthy, B., Ye, Y., Sun, W., Lin, J., Wang, T., Fine, J., et al. (2018) · Advanced Materials · doi:10.1002/adma.201707112 · Cited by 290
Converting Cold into Hot Tumors by Combining Immunotherapies
Haanen, J. B. A. G. (2017) · Cell · doi:10.1016/j.cell.2017.08.031 · Cited by 264
Zhao, X., Yang, K., Zhao, R., Ji, T., Wang, X., Yang, X., Zhang, Y., Cheng, K., Liu, S., Hao, J., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.032 · Cited by 256
Self-citationEngineering PD-1-Presenting Platelets for Cancer Immunotherapy
Zhang, X., Wang, J., Chen, Z., Hu, Q., Wang, C., Yan, J., Dotti, G., Huang, P., & Gu, Z. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02321 · Cited by 232
Bioengineered bacterial vesicles as biological nano-heaters for optoacoustic imaging
Gujrati, V., Prakash, J., Malekzadeh-Najafabadi, J., Stiel, A., Klemm, U., Mettenleiter, G., Aichler, M., Walch, A., & Ntziachristos, V. (2019) · Nature Communications · doi:10.1038/s41467-019-09034-y · Cited by 215
Basic Overview of Current Immunotherapy Approaches in Cancer
Velcheti, V., & Schalper, K. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_156572 · Cited by 176
Chen, J., Feng, Y., Lu, L., Wang, H., Dai, L., Li, Y., & Zhang, P. (2012) · Immunobiology · doi:10.1016/j.imbio.2011.10.016 · Cited by 164
Self-citationThay, B., Damm, A., Kufer, T. A., Wai, S. N., & Oscarsson, J. (2014) · Infection and Immunity · doi:10.1128/iai.01980-14 · Cited by 148
Rappazzo, C. G., Watkins, H. C., Guarino, C., Chau, A., Lopez, J. L., DeLisa, M. P., Leifer, C. A., Whittaker, G. R., & Putnam, D. A. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.01.028 · Cited by 141
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
Jelínek, T., Paiva, B., & Hájek, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02431 · Cited by 118
Bacterial Protoplast-Derived Nanovesicles as Vaccine Delivery System against Bacterial Infection
Kim, O. Y., Choi, S. J., Jang, S. C., Park, K., Kim, S. R., Choi, J. P., Lim, J. H., Lee, S., Park, J., Vizio, D. D., et al. (2014) · Nano Letters · doi:10.1021/nl503508h · Cited by 112
Rožman, P. J., & Švajger, U. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.04.001 · Cited by 90
Lee, D. H., Kim, S., Kang, W., Choi, Y. S., Lee, S. H., Lee, S., You, S., Lee, H. K., Chang, K.-T., & Shin, E. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.08.102 · Cited by 74
Nanobodies in therapeutic applications.
Roovers, R. C., van Dongen, G. A. M. S., & Henegouwen, P. M. P. V. B. E. (2007) · PubMed · Cited by 72
Nagahara, M., Mimori, K., Kataoka, A., Ishii, H., Tanaka, F., Nakagawa, T., Sato, T., Ono, S., Sugihara, K., & Mori, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0349 · Cited by 65
The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer
Shibata, T., Lieblong, B. J., Sasagawa, T., & Nakagawa, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.07.001 · Cited by 54
Starnes, C. O. (1992) · Nature · doi:10.1038/360023b0 · Cited by 53
The anti-PD-1 era — an opportunity to enhance radiotherapy for patients with bladder cancer
Walshaw, R. C., Honeychurch, J., Illidge, T., & Choudhury, A. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.172 · Cited by 42
Kuczynski, E. A., Krueger, J., Chow, A., Xu, P., Man, S., Sundaravadanam, Y., Miller, J. K., Krzyzanowski, P. M., & Kerbel, R. S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1091 · Cited by 30
Cited by
Cheng, K., Zhao, R., Li, Y., Qi, Y., Wang, Y., Zhang, Y., Qin, H., Qin, Y., Chen, L., Li, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22308-8 · Cited by 480
Self-citationYue, Y., Xu, J., Li, Y., Cheng, K., Feng, Q., Ma, X., Ma, N., Zhang, T., Wang, X., Zhao, X., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00886-2 · Cited by 264
Self-citationLi, Y., Ma, X., Yue, Y., Zhang, K., Cheng, K., Feng, Q., Ma, N., Liang, J., Zhang, T., Zhang, L., et al. (2022) · Advanced Materials · doi:10.1002/adma.202109984 · Cited by 247
Self-citationWang, J., Zhu, M., & Nie, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113974 · Cited by 153
Self-citationWang, J., Liang, S., Chen, S., Ma, T., Chen, M., Niu, C., Leng, Y., & Wang, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02619-w · Cited by 53
Metadata
- Authors
- Li, Y., Zhao, R., Cheng, K., Zhang, K., Wang, Y., Zhang, Y., Li, Y., Liu, G., Xu, J., Xu, J., Anderson, G. J., Shi, J., Ren, L., Zhao, X., & Nie, G.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-11-24
- Volume
- 14
- Issue
- 12
- Pages
- 16698-16711
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W3108623682
- Cited by
- 282
- References
- 38
- FWCI
- 10.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.